MALIGNANT MELANOMA

This is an early safety study testing a new drug called PF-08046037, both alone and combined with another immunotherapy drug (sasanlimab), in people with advanced cancers. The study is enrolling a small group of people with specific advanced cancers like lung, head and neck, mela…

This study is testing whether adding an oral drug called DEC-C to a standard immunotherapy (nivolumab) can make treatment more effective for people with advanced mucosal melanoma that cannot be removed by surgery. The goal is to see if this combination is safe and can better cont…

This study is for people with a specific type of advanced skin cancer (melanoma) that has spread to the brain. It tests whether adding a precise, high-dose radiation treatment (stereotactic radiosurgery) to a combination of three drugs works better than the drugs alone. The goal …

This study is testing whether adding one of two experimental cancer vaccines (SCIB1 or iSCIB1+) to standard immunotherapy drugs can improve outcomes for people with advanced, inoperable melanoma. The goal is to see if the vaccines help patients respond better to treatment and kee…

This study tested a combination of two drugs, temozolomide and peginterferon, to see how well they work in children with high-risk or advanced melanoma. The goal was to see if the treatment could shrink tumors and prevent the cancer from coming back. Children were placed in diffe…